3
Announcements
Trials
Browse
Landscape
Status
Completed
174
Terminated
53
Recruiting
27
Withdrawn
15
Active not recruiting
15
Unknown
7
Not yet recruiting
4
Suspended
1
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Leukemia
6
Recurrence
3
Myelodysplastic Syndromes
3
Precancerous Conditions
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Graft vs Host Disease
2
Blast Crisis
2
Waldenstrom Macroglobulinemia
1
Primary Myelofibrosis
1
Preleukemia
1
Pancytopenia
1
Osteosclerosis
1
Osteopetrosis
1
Osteochondrodysplasias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Musculoskeletal Diseases
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Mastocytosis, Systemic
1
Interventions
venetoclax
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
Primary Myelofibrosis
×
Other hematologic neoplasm
×
Clear all
NCT03592576
2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available